Treatment  	Treatment  	 NN	O
of  	of  	 IN	O
rheumatic  	rheumatic  	 JJ	B-NP
diseases  	diseases  	 NNS	I-NP
and  	and  	 CC	O
hepatitis  	hepatitis  	 NNP	B-NP
B  	B  	 NNP	I-NP
virus  	virus  	 NN	I-NP
coinfection  	coinfection  	 VBD	O
We  	We  	 PRP	O
often  	often  	 RB	O
encounter  	encounter  	 VB	O
rheumatological  	rheumatological  	 JJ	B-NP
patients  	patients  	 NNS	I-NP
coinfected  	coinfected  	 VBN	O
with  	with  	 IN	O
hepatitis  	hepatitis  	 NNP	B-NP
B  	B  	 NNP	I-NP
in  	in  	 IN	O
daily  	daily  	 JJ	O
practice 	practice 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
paper 	paper 	 NN	O
,  	,  	 ,	O
we  	we  	 PRP	O
will  	will  	 MD	O
discuss  	discuss  	 VB	O
the  	the  	 DT	O
basic  	basic  	 JJ	O
characteristics  	characteristics  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
virus  	virus  	 NN	O
of  	of  	 IN	O
hepatitis  	hepatitis  	 NNP	B-NP
B 	B 	 NNP	I-NP
,  	,  	 ,	O
course  	course  	 NN	O
of  	of  	 IN	O
infection 	infection 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
safety  	safety  	 NN	O
of  	of  	 IN	O
rituximab 	rituximab 	 NN	B-NP
,  	,  	 ,	O
tocilizumab 	tocilizumab 	 NN	B-NP
,  	,  	 ,	O
abatacept  	abatacept  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
and  	and  	 CC	O
therapeutic  	therapeutic  	 JJ	B-NP
recommendations  	recommendations  	 NNS	I-NP
in  	in  	 IN	O
management  	management  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
rheumatic  	rheumatic  	 JJ	B-NP
diseases 	diseases 	 NNS	I-NP
.  	.  	 .	O
